Cerebrotendinous Xanthomatosis Market is segmented By Treatment Type (Marketed Drugs, Emerging Drugs), By Geography (North America, Latin America, Asia Pacific, Europe, M ....
Market Size in USD
CAGR11.5%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 11.5% |
Market Concentration | High |
Major Players | Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Idorsia Pharmaceuticals Ltd., Intercept Pharmaceuticals, Inc., Merck & Co., Inc. |
The cerebrotendinous xanthomatosis market is estimated to be valued at USD 167.3 Mn in 2024 and is expected to reach USD 359.5 Mn by 2031, growing at a compound annual growth rate (CAGR) of 11.5% from 2024 to 2031. Recent discoveries about the genetic origins and treatment of the condition have driven increased diagnosis and treatment uptake over the past 5 years.